openPR Logo
Press release

Hepatocellular Carcinoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

07-10-2024 01:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hepatocellular Carcinoma Pipleine

Hepatocellular Carcinoma Pipleine

Hepatocellular Carcinoma companies are Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, more.
(Albany, USA) As per DelveInsight's assessment, globally, about 90+ key pharma and biotech companies are working on 95+ pipeline drugs in the Hepatocellular Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Hepatocellular Carcinoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatocellular Carcinoma Therapeutics Market. The report provides a detailed description of the Hepatocellular Carcinoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Hepatocellular Carcinoma Clinical Trial Activities and Regulatory Developments in the domain @ Hepatocellular Carcinoma Pipeline Analysis [https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Hepatocellular Carcinoma Pipeline are:

* Hepatocellular Carcinoma Companies across the globe are diligently working toward developing novel Hepatocellular Carcinoma treatment therapies with a considerable amount of success over the years.
* Hepatocellular Carcinoma companies working in the treatment market are Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCap Zoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others, are developing therapies for the Hepatocellular Carcinoma treatment
* Emerging Hepatocellular Carcinoma therapies in the different phases of clinical trials are Namodenoson, SRF388, Porustobart, Fisogatinib, STP705, and others are expected to have a significant impact on the Hepatocellular Carcinoma market in the coming years.

Hepatocellular Carcinoma (HCC) Pipeline Analysis

The report provides insights into:

* The report provides detailed insights into the key companies that are developing Hepatocellular Carcinoma therapies.
* The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma treatment.
* It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* It navigates the emerging Hepatocellular Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hepatocellular Carcinoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Hepatocellular Carcinoma Therapeutics Domain @ Hepatocellular Carcinoma FDA Approvals and Advancements [https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatocellular Carcinoma (HCC) Therapeutics Analysis

About 90+ notable companies are actively involved in developing therapies for Hepatocellular Carcinoma (HCC). Among them, Can-Fite BioPharma stands out as a key player, advancing its HCC drug candidates to the most advanced stage, Phase III.

Hepatocellular Carcinoma Companies in the Therapeutics Market Include:

Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCap Zoom Biosciences, Eutilex, Polaris Pharmaceuticals, and OriCell Therapeutics are the leading pharma giants shaping the landscape of the Hepatocellular Carcinoma Therapeutic Market.

Emerging and Marketed Hepatocellular Carcinoma Therapies Covered in the Report Include:

* Namodenoson: Can-Fite BioPharma
* SRF388: Surface Oncology
* Porustobart: Harbour BioMed
* Fisogatinib: CStone Pharmaceuticals
* STP705: Sirnaomics
* And Many Others

Get an in-depth Assessment of the Emerging Therapies and Hepatocellular Carcinoma Companies Actively Working in the Market @ Hepatocellular Carcinoma Drugs in Pipeline [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Hepatocellular Carcinoma Drugs Uptake

The Report Covers the Emerging Hepatocellular Carcinoma Therapies Under Different Phases of Clinical Development Like -

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued and inactive candidates

Route of Administration

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Molecule Type

Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Request for Sample PDF to Understand More About the Hepatocellular Carcinoma Treatment Outlook and Future Perspectives @ Hepatocellular Carcinoma Drugs and Therapies [https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Hepatocellular Carcinoma Current Treatment Patterns

4. Hepatocellular Carcinoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Hepatocellular Carcinoma Late-Stage Products (Phase-III)

7. Hepatocellular Carcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hepatocellular Carcinoma Discontinued Products

13. Hepatocellular Carcinoma Product Profiles

14. Hepatocellular Carcinoma Companies

15. Hepatocellular Carcinoma Drugs

16. Dormant and Discontinued Products

17. Hepatocellular Carcinoma Unmet Needs

18. Hepatocellular Carcinoma Future Perspectives

19. Hepatocellular Carcinoma Analyst Review

20. Appendix

21. Report Methodology

Latest Report:

Urolithiasis market [https://www.delveinsight.com/report-store/urolithiasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

DelveInsight's "Urolithiasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Urolithiasis, historical and forecasted epidemiology as well as the Urolithiasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatocellular-carcinoma-pipeline-analysis-2024-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatocellular Carcinoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight here

News-ID: 3574451 • Views:

More Releases from ABNewswire

Major Maids House Cleaners: Exceptional St Pete House Cleaners Now Available In St. Petersburg, FL
Major Maids House Cleaners: Exceptional St Pete House Cleaners Now Available In …
Major Maids House Cleaners in St. Petersburg, FL, provides outstanding cleaning services. They shine in the industry with a stellar reputation, meticulous attention to detail, and a commitment to eco-friendly practices. Major Maids House Cleaners [https://www.majormaidshomecleaning.com/florida/st-petersburg] in St. Petersburg, FL, delivers exceptional services. They stand out in the industry with a stellar reputation, meticulous attention to detail, and an eco-conscious approach. Services range from regular to deep cleaning, addressing various needs
Experience Top-Notch Home Cleaning with Bright Side Services Inc.'s Maid Services
Experience Top-Notch Home Cleaning with Bright Side Services Inc.'s Maid Service …
Bright Side Services Inc.'s maid services encompass a comprehensive range of cleaning tasks, ensuring every aspect of your home receives thorough attention. From dusting and vacuuming to polishing surfaces and sanitising bathrooms, their professional cleaners are trained to deliver impeccable results. Whether you require a one-time deep clean or regular maintenance, their services can be tailored to meet your specific needs. In the realm of home maintenance, the demand for meticulous
Experience the Difference: Bright Side Services Inc. Launches Residential Cleaning Solutions
Experience the Difference: Bright Side Services Inc. Launches Residential Cleani …
In the ever-evolving world of home maintenance, the importance of a pristine living environment cannot be overstated. Recognising this necessity, Bright Side Services Inc. has introduced their exceptional residential cleaning services [https://brightsideservicesinc.com/#:~:text=busy%20schedule.%20Our-,residential%20cleaning%20services,-include%3A]. These offerings are designed to meet the needs of modern homeowners, providing comprehensive solutions that ensure every corner of your home gleams with cleanliness. Bright Side Services Inc. has built a reputation for excellence, and the launch of their
FunPartyCos Introduces a Diverse Range of Spiderman Costumes for Fans of All Ages
FunPartyCos Introduces a Diverse Range of Spiderman Costumes for Fans of All Age …
The world of cosplay has always been a vibrant space where fans can immerse themselves in the roles of their favorite characters. FunPartyCos, a leading provider of cosplay costumes, has unveiled an exciting lineup of Spiderman costumes designed to cater to fans of all ages and genders. Speaking on behalf of FunPartyCos, Sarah Johnson, the Cosplay Specialist, emphasized the inclusivity of their Spiderman costume collection. "Our goal at FunPartyCos is to

All 5 Releases


More Releases for Hepatocellular

Hepatocellular Carcinoma Drugs Market Opportunity Analysis, 2018-2026
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy
Hepatocellular Carcinoma HCC Treatment Market: Global Forecast over 2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Global Clinical Trials Review H2 2017
ReportsWeb.com published “Hepatocellular Carcinoma Global Clinical Trials Review H2 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: Publisher's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular
Trends in the Hepatocellular Carcinoma HCC Treatment Market 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated
Hepatocellular Carcinoma Market 2024: Opportunity Analysis and Forecasts
"The Latest Research Report OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Hepatocellular Carcinoma Market Liver cancer is the second leading cause of cancer related death in the world in men and the sixth leading cause of cancer death in women. Hepatocellular carcinoma (HCC) is the most dominant form of liver
Hepatocellular Carcinoma HCC Treatment Market Growth and Forecast 2016-2026
Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation. The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated